Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Overview | 11 | 1 |
| Therapeutics Development | 12 | 3 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Stage of Development | 12 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Therapy Area | 13 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Indication | 14 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Companies | 17 | 4 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Universities/Institutes | 21 | 2 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Therapeutics Assessment | 23 | 6 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Companies Involved in Therapeutics Development | 29 | 24 |
| Ablynx NV | 29 | 1 |
| Agilvax, Inc. | 30 | 1 |
| Aridis Pharmaceuticals LLC | 31 | 1 |
| Bavarian Nordic A/S | 32 | 1 |
| Celltrion, Inc. | 33 | 1 |
| Emergent BioSolutions Inc. | 34 | 1 |
| F. Hoffmann-La Roche Ltd. | 35 | 1 |
| Gene Techno Science Co., Ltd. | 36 | 1 |
| GenVec, Inc. | 37 | 1 |
| Gilead Sciences, Inc. | 38 | 1 |
| GlaxoSmithKline Plc | 39 | 1 |
| iBio, Inc. | 40 | 1 |
| Johnson &Johnson | 41 | 1 |
| mAbxience S.A. | 42 | 1 |
| MedImmune, LLC | 43 | 1 |
| Medivir AB | 44 | 1 |
| Mucosis B.V. | 45 | 1 |
| Navigen Pharmaceuticals, Inc. | 46 | 1 |
| Novavax, Inc. | 47 | 1 |
| Regeneron Pharmaceuticals, Inc. | 48 | 1 |
| Takeda Pharmaceutical Company Limited | 49 | 1 |
| The International Biotechnology Center (IBC) Generium | 50 | 1 |
| Vaxart, Inc. | 51 | 1 |
| VLP Biotech, Inc. | 52 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Drug Profiles | 53 | 54 |
| (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine Drug Profile | 53 | 1 |
| (influenza (virus like particle) + respiratory syncytial virus) vaccine Drug Profile | 54 | 1 |
| AK-0529 Drug Profile | 55 | 1 |
| ALX-0171 Drug Profile | 56 | 3 |
| AR-201 Drug Profile | 59 | 1 |
| GNR-007 Drug Profile | 60 | 1 |
| GV-2311 Drug Profile | 61 | 2 |
| JNJ-61187165AAA Drug Profile | 63 | 1 |
| JNJ-61187191AAA Drug Profile | 64 | 1 |
| MEDI-7510 Drug Profile | 65 | 2 |
| MEDI-8897 Drug Profile | 67 | 1 |
| Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections Drug Profile | 68 | 1 |
| Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections Drug Profile | 69 | 1 |
| MVA-RSV Drug Profile | 70 | 1 |
| palivizumab biosimilar Drug Profile | 71 | 1 |
| palivizumab biosimilar Drug Profile | 72 | 1 |
| palivizumab biosimilar Drug Profile | 73 | 1 |
| palivizumab biosimilar Drug Profile | 74 | 1 |
| palivizumab biosimilar Drug Profile | 75 | 1 |
| presatovir Drug Profile | 76 | 2 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 78 | 1 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 79 | 1 |
| respiratory syncytial virus (virus like particle) vaccines Drug Profile | 80 | 1 |
| respiratory syncytial virus immune globulin (human) Drug Profile | 81 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 82 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 83 | 10 |
| respiratory syncytial virus vaccine Drug Profile | 93 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 94 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 95 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 96 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 97 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 98 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 99 | 1 |
| RSV-001 Drug Profile | 100 | 1 |
| RV-521 Drug Profile | 101 | 1 |
| Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections Drug Profile | 102 | 1 |
| suptavumab Drug Profile | 103 | 1 |
| SynGEM Drug Profile | 104 | 2 |
| Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection Drug Profile | 106 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Dormant Projects | 107 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Discontinued Products | 108 | 1 |
| Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Featured News &Press Releases | 109 | 11 |
| Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program | 109 | 1 |
| May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults | 110 | 1 |
| May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations | 111 | 1 |
| May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalised with a RSV infection | 111 | 2 |
| Mar 09, 2016: First consortium of local manufacturers to make affordable biosimilars available for low income countries | 113 | 1 |
| Mar 04, 2016: Immune Design s GLAAS Platform Shown to Modulate the Allergic Immune Response | 113 | 1 |
| Jan 20, 2016: Mucosis Secures 3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London | 114 | 1 |
| Dec 21, 2015: Novavax Appoints Mark Twyman Vice President Marketing | 115 | 1 |
| Dec 17, 2015: Ablynx Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants | 115 | 1 |
| Dec 14, 2015: Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults | 116 | 1 |
| Dec 03, 2015: Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization | 116 | 1 |
| Nov 19, 2015: Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference | 117 | 1 |
| Nov 16, 2015: Novavax to Make Multiple Presentations at RSV Vaccines for the World | 118 | 1 |
| Nov 09, 2015: Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults | 118 | 1 |
| Oct 29, 2015: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS Discovery Platform | 119 | 1 |
| Appendix | 120 | 2 |
| Methodology | 120 | 1 |
| Coverage | 120 | 1 |
| Secondary Research | 120 | 1 |
| Primary Research | 120 | 1 |
| Expert Panel Validation | 120 | 1 |
| Contact Us | 120 | 1 |
| Disclaimer | 121 | 1 |